Results 21 to 30 of about 18,333 (163)

Abstract Book for the 27th Congress of the European Hematology Association

open access: yes, 2022
HemaSphere, Volume 6, Issue S3, Page 1-4130, June 2022.
wiley   +1 more source

PF684 ANAGRELIDE MODULATES PROPLATELET FORMATION RESULTING IN DECREASED NUMBER AND INCREASED SIZE OF PLATELETS

open access: yesHemaSphere, Volume 3, Issue S1, Page 296, June 2019., 2019
Background: In patients with essential thrombocythemia (ET) who have high risk factors for thrombotic events, cytoreductive therapy with anagrelide (ANA) or hydroxycarbamide (HC) is one of the treatment options. Despite the clinically evident platelet‐lowering effect of ANA, the detailed mechanism of its effect remains to be elucidated.
N. Miyashita   +4 more
wiley   +1 more source

Filantropía y asistencialismo. Fórmulas de legitimación de los programas de contratación en origen de temporeros agrícolas extranjeros en Cataluña

open access: yesRelaciones Internacionales, 2017
En el presente trabajo abordamos críticamente el papel que ha jugado la principal organización empresarial catalana, Unió de Pagesos (UP), como gestora de proyectos asistencialistas en Cataluña y de codesarrollo en Colombia, establecidos al alero de las ...
Olga ACHÓN RODRÍGUEZ
doaj   +1 more source

PF685 THE RELATIONSHIP BETWEEN TOTAL ANTIOXIDANT CAPACITY AND JAK2V617F MUTATION IN ESSENTIAL THROMBOCYTHEMIA

open access: yesHemaSphere, Volume 3, Issue S1, Page 296-297, June 2019., 2019
Background: Essential thrombocythemia (ET) is a BCR‐ABL1‐negative myeloproliferative neoplasm associated in 50–60% of cases with the presence of the JAK2V617F mutation. Several studies have revealed that oxidative stress induces a growth advantage to JAK2V617F‐ positive clones, but little is known about the antioxidant status of ET patients.
M.‐A. Gaman, C. Moisa, A.M. Gaman
wiley   +1 more source

EHA2021 Virtual Congress Abstract Book

open access: yes, 2021
HemaSphere, Volume 5, Issue S2, June 2021.
wiley   +1 more source

PB1923 PONATINIB LONG‐TERM FOLLOW‐UP OF EFFICACY AND SAFETY IN CP‐CML PATIENTS IN REAL WORLD SETTINGS IN FRANCE: THE POST‐PACE STUDY

open access: yesHemaSphere, Volume 3, Issue S1, Page 874-875, June 2019., 2019
Background: Ponatinib (PON) is a third generation tyrosine kinase inhibitor (TKI) used in adults with chronic myeloid leukaemia (CML) or Ph+ acute lymphoblastic leukaemia who are resistant or intolerant to prior TKIs or those harbouring the BCR‐ABL1T315I mutant.
F.‐E. Nicolini   +7 more
wiley   +1 more source

El Museo Social Argentino (1911-1925). Los vínculos de los reformadores sociales en el Cono Sur de América

open access: yesQuinto Sol, 2020
Las instituciones con vocación internacional son una excelente entrada para estudiar la conformación de la realidad social sudamericana, en un contexto de desarrollo del panamericanismo y de las agencias pertenecientes a la Sociedad de las Naciones ...
Juan Carlos Yáñez Andrade
doaj   +1 more source

PB1925 COMPARATIVE STUDY OF GLIVEC VERSUS STATE SPONSORED GENERIC IMATINIB MESYLATE AS FIRST LINE THERAPY IN CHRONIC MYELOID LEUKEMIA‐ CHRONIC PHASE

open access: yesHemaSphere, Volume 3, Issue S1, Page 875, June 2019., 2019
Background: In a developing economy like India, Imatinib usage has increased manifold after generic formulations were introduced. 25 brands of generic Imatinib are approved by the Drug Controller General of India. The efficacy and safety of these brands have been repeatedly questioned by different studies.
A. Iqbal   +4 more
wiley   +1 more source

Filantropía, asistencia y epidemias en Brasil [PDF]

open access: yes, 2011
Los acalorados debates promovidos por la propuesta del presidente Barak Obama sobre la reforma del sistema de salud en Estados Unidos buscando la ampliación del alcance de los servicios de salud para llegar hasta el 97% de los norte-americanos en el ...
Ferreira, Luiz Otávio   +4 more
core   +4 more sources

PB1926 THE RELATIONSHIP BETWEEN OXIDATIVE STRESS LEVELS, BCR‐ABL1 TRANSCRIPT VALUES AND TREATMENT WITH TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

open access: yesHemaSphere, Volume 3, Issue S1, Page 875-876, June 2019., 2019
Background: Chronic myeloid leukaemia (CML) is a chronic myeloproliferative neoplasm associated with a BCR‐ABL1 gene sequence. Some studies have shown that oxidative stress is involved in CML pathogenesis, genomic instability, disease progression and resistance to tyrosine‐kinase inhibitors (TKI).
E.G. Pascu, M.‐A. Gaman, A.M. Gaman
wiley   +1 more source

Home - About - Disclaimer - Privacy